PODD

1 Day 1D

5 Days 5D

1 Month 1M

6 Months 6M

YTD YTD

1 Year 1Y

5 Years 5Y

About Insulet Corporation

Insulet Corporation , headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas.
CEO
Shacey Petrovic
Employees
1900
Headquarters

100 Nagog Park
Acton, Massachusetts 01720-3440
Phone: 19786007000
www.myomnipod.com

News

Insulet Corporation Reports Record-Breaking Financial Performance in Fourth Quarter of 2023
Feb 23, 2024 19:24pm

Insulet Corporation (NASDAQ: PODD), a global leader in tubeless insulin pump technology, has reported impressive financial results for the period of October to December 31, 2023. The companyns EPS soared by a remarkable 406.92% to $1.22 per share compared to the previous year, while revenue grew by 37.896% to $509.80 million.One interesting fact to note is that Insulet Corporationns revenue growth outpaced that of its industry peers. In the fourth quarter of 2023, the company experienced a revenue advance of 7.82%, while the average growth for the Medical Equipment and Supplies sector was only 7.82% from the same period the previous year.Additionally, Insulet Corporation saw a significant increase in its bottom-line, with net earnings rising by 507.65% to $103.3 million in the October to December 31, 2023 span. This is compared to the net earnings of $17 million reported in the same period the previous year.The companyns improving profit margins are also worth noting. Insulet Corporation saw its net margin rise to 20.


Source:CSIMarket
Earnings call: Insulet sees strong Q4 growth, aims for market leadership
Feb 23, 2024 08:57am

https://www.investing.com/news/stock-market-news/earnings-call-insulet-sees-strong-q4-growth-aims-for-market-leadership-93CH-3312513


Source:Investing.com
Insulet Corporation (PODD) Q4 2023 Earnings Call Transcript
Feb 23, 2024 00:55am

No summary available.


Source:Seeking Alpha
Insulet forecasts weak annual revenue growth; shares drop
Feb 22, 2024 23:00pm

https://www.investing.com/news/stock-market-news/insulet-beats-quarterly-profit-estimates-on-strong-demand-for-insulin-pumps-3311990


Source:Investing.com
Insulet Non-GAAP EPS of $1.40 beats by $0.74, revenue of $509.8M beats by $48.74M
Feb 22, 2024 21:33pm

No summary available.


Source:Seeking Alpha
Insulet Corp (PODD) Reports Robust Full Year and Q4 2023 Financial Results
Feb 22, 2024 21:32pm

Insulet Corp (PODD) Reports Robust Full Year and Q4 2023 Financial Results


Source:GuruFocus
Insulet gets CE Mark for Ominipod 5 with FreeStyle Libre 2 sensor
Feb 07, 2024 15:11pm

No summary available.


Source:Seeking Alpha
Banque Cantonale Vaudoise Decreases Stock Position in Insulet Co. (NASDAQ:PODD)
Feb 07, 2024 12:42pm

Banque Cantonale Vaudoise cut its stake in shares of Insulet Co. (NASDAQ:PODD – Free Report) by 38.3% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 4,276 shares of the medical instruments supplier’s stock after selling 2,651 shares during the period. Banque […]


Source:The AM Reporter
Insulet Corporation: Insulet Announces CE Mark Approval of Omnipod 5 Integration with Abbott FreeStyle Libre 2 Plus Sensor
Feb 07, 2024 11:06am

Omnipod 5 is the world''s first tubeless automated insulin delivery system to achieve CE mark approval with multiple continuous glucose monitoring (CGM) sensor brands. Latest Omnipod 5 integration …


Source:Finanz Nachrichten
Insulet Announces CE Mark Approval of Omnipod 5 Integration with Abbott FreeStyle Libre 2 Plus Sensor
Feb 07, 2024 11:00am

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod brand of products, today announced it has received CE mark approval under the European Medical Device Regulation for the added compatibility of the Abbott FreeStyle Libre 2 Plus sensor with Insulet’s Omnipod 5 Automated Insulin Delivery System for individuals aged


Source:Wallstreet:Online